Steven Valiquette
Stock Analyst at Mizuho
(3.60)
# 890
Out of 5,127 analysts
123
Total ratings
56.92%
Success rate
5.09%
Average return
Main Sectors:
Stocks Rated by Steven Valiquette
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DOCS Doximity | Maintains: Neutral | $45 → $34 | $27.24 | +24.82% | 4 | Feb 10, 2026 | |
| NVST Envista Holdings | Maintains: Neutral | $24 → $27 | $30.17 | -10.51% | 4 | Feb 10, 2026 | |
| CAH Cardinal Health | Maintains: Outperform | $222 → $235 | $220.27 | +6.69% | 8 | Feb 6, 2026 | |
| MCK McKesson | Maintains: Neutral | $880 → $885 | $935.21 | -5.37% | 5 | Feb 5, 2026 | |
| HSIC Henry Schein | Maintains: Neutral | $74 → $81 | $81.04 | -0.04% | 6 | Jan 20, 2026 | |
| XRAY DENTSPLY SIRONA | Maintains: Neutral | $13 → $14 | $13.93 | +0.50% | 8 | Jan 20, 2026 | |
| ALGN Align Technology | Maintains: Outperform | $170 → $200 | $196.27 | +1.90% | 13 | Jan 20, 2026 | |
| SOLV Solventum | Upgrades: Outperform | $85 → $100 | $80.46 | +24.29% | 3 | Jan 20, 2026 | |
| MDLN Medline | Initiates: Outperform | $48 | $45.29 | +5.98% | 1 | Jan 12, 2026 | |
| PHR Phreesia | Maintains: Outperform | $36 → $28 | $12.41 | +125.62% | 2 | Dec 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $6 | $3.05 | +96.72% | 2 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5 → $4 | $2.33 | +71.67% | 1 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $340 → $380 | $360.00 | +5.56% | 3 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $50 | $23.50 | +112.77% | 2 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $295 → $325 | $186.99 | +73.81% | 4 | Aug 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $10 | $4.85 | +106.19% | 1 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $126 | $78.35 | +60.82% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $3.90 | +28.21% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $142 | $212.78 | -33.26% | 10 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 | $83.90 | -34.45% | 6 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $92 | $200.84 | -54.19% | 10 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $565 | $273.22 | +106.79% | 5 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $100 | $75.70 | +32.10% | 1 | Mar 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $380 → $400 | $125.43 | +218.90% | 4 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $107 | $39.61 | +170.13% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $22 → $17 | $38.74 | -56.12% | 3 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $5 → $12 | $16.29 | -26.34% | 1 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $96 | $109.00 | -11.93% | 3 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $105 → $120 | $205.35 | -41.56% | 6 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $117 → $127 | $502.05 | -74.70% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $327 → $358 | $181.30 | +97.46% | 3 | Dec 6, 2019 |
Doximity
Feb 10, 2026
Maintains: Neutral
Price Target: $45 → $34
Current: $27.24
Upside: +24.82%
Envista Holdings
Feb 10, 2026
Maintains: Neutral
Price Target: $24 → $27
Current: $30.17
Upside: -10.51%
Cardinal Health
Feb 6, 2026
Maintains: Outperform
Price Target: $222 → $235
Current: $220.27
Upside: +6.69%
McKesson
Feb 5, 2026
Maintains: Neutral
Price Target: $880 → $885
Current: $935.21
Upside: -5.37%
Henry Schein
Jan 20, 2026
Maintains: Neutral
Price Target: $74 → $81
Current: $81.04
Upside: -0.04%
DENTSPLY SIRONA
Jan 20, 2026
Maintains: Neutral
Price Target: $13 → $14
Current: $13.93
Upside: +0.50%
Align Technology
Jan 20, 2026
Maintains: Outperform
Price Target: $170 → $200
Current: $196.27
Upside: +1.90%
Solventum
Jan 20, 2026
Upgrades: Outperform
Price Target: $85 → $100
Current: $80.46
Upside: +24.29%
Medline
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $45.29
Upside: +5.98%
Phreesia
Dec 10, 2025
Maintains: Outperform
Price Target: $36 → $28
Current: $12.41
Upside: +125.62%
Nov 19, 2025
Maintains: Neutral
Price Target: $8 → $6
Current: $3.05
Upside: +96.72%
Nov 6, 2025
Maintains: Neutral
Price Target: $5 → $4
Current: $2.33
Upside: +71.67%
Nov 6, 2025
Maintains: Outperform
Price Target: $340 → $380
Current: $360.00
Upside: +5.56%
Oct 30, 2025
Maintains: Outperform
Price Target: $48 → $50
Current: $23.50
Upside: +112.77%
Aug 29, 2025
Maintains: Outperform
Price Target: $295 → $325
Current: $186.99
Upside: +73.81%
Jul 25, 2025
Initiates: Neutral
Price Target: $10
Current: $4.85
Upside: +106.19%
Dec 4, 2024
Initiates: Outperform
Price Target: $126
Current: $78.35
Upside: +60.82%
Dec 4, 2024
Initiates: Outperform
Price Target: $5
Current: $3.90
Upside: +28.21%
Sep 21, 2023
Maintains: Equal-Weight
Price Target: $142
Current: $212.78
Upside: -33.26%
Aug 4, 2023
Maintains: Overweight
Price Target: $55
Current: $83.90
Upside: -34.45%
Aug 2, 2023
Maintains: Overweight
Price Target: $82 → $92
Current: $200.84
Upside: -54.19%
Apr 14, 2023
Maintains: Overweight
Price Target: $565
Current: $273.22
Upside: +106.79%
Mar 30, 2023
Maintains: Overweight
Price Target: $110 → $100
Current: $75.70
Upside: +32.10%
Oct 28, 2022
Maintains: Overweight
Price Target: $380 → $400
Current: $125.43
Upside: +218.90%
Jul 28, 2022
Reinstates: Overweight
Price Target: $107
Current: $39.61
Upside: +170.13%
Apr 18, 2022
Downgrades: Equal-Weight
Price Target: $22 → $17
Current: $38.74
Upside: -56.12%
Jun 11, 2021
Upgrades: Overweight
Price Target: $5 → $12
Current: $16.29
Upside: -26.34%
Nov 23, 2020
Upgrades: Overweight
Price Target: $96
Current: $109.00
Upside: -11.93%
Apr 30, 2020
Reiterates: Neutral
Price Target: $105 → $120
Current: $205.35
Upside: -41.56%
Apr 22, 2020
Maintains: Overweight
Price Target: $117 → $127
Current: $502.05
Upside: -74.70%
Dec 6, 2019
Maintains: Overweight
Price Target: $327 → $358
Current: $181.30
Upside: +97.46%